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Abstract
Tetrahydrobiopterin (BH4) is an essential cofactor and an important cellular antioxidant. BH4
deficiency has been associated with diseases whose etiologies stem from excessive oxidative
stress. GTP cyclohydrolase I (GCH1) catalyzes the first and rate-limiting step of de novo BH4
synthesis. A 3-SNP haplotype in GCH1 (rs8007267, rs3783641, and rs10483639) is known to
modulate GCH1 gene expression levels and has been suggested as a major determinant of plasma
BH4 bioavailability. As plasma BH4 bioavailability has been suggested as a mechanism of neural
tube defect (NTD) teratogenesis, we evaluated the association between this GCH1 haplotype and
the risk of NTDs. Samples were obtained from 760 NTD case-parent triads included in the
National Birth Defects Prevention Study (NBDPS). The three SNPs were genotyped using
TaqMan® SNP assays. An extension of the log-linear model was used to assess the association
between NTDs and both offspring and maternal haplotypes. Offspring carrying two copies of
haplotype C-T-C had a significantly increased NTD risk (risk ratio [RR] = 3.40, 95% confidence
interval [CI]: 1.02–11.50), after adjusting for the effect of the maternal haplotype. Additionally,
mothers carrying two copies of haplotype C-T-C had a significantly increased risk of having an
NTD-affected offspring (RR = 3.46, 95% CI: 1.05–11.00), after adjusting for the effect of the
offspring haplotype. These results suggest offspring and maternal variation in the GCH1 gene and
altered BH4 biosynthesis may contribute to NTD risk.
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Tetrahydrobiopterin (BH4) is a naturally occurring nutrient and an essential cofactor for
several important biological processes. A deficit in biosynthesis or regeneration of BH4 may
result in nitric oxide (NO) deficiency and oxidative stress. BH4 is a cofactor for nitric oxide
synthase, which regulates methionine synthase (MS) activity and neural tube closure. In
chick embryos, the inhibition of BH4 biosynthesis reduces MS activity and leads to defects
in neural tube closure [1, 2].
Serum BH4 concentrations are regulated by the enzymes GTP cyclohydrolase I (GCH1), 6-
pyruvoyl-tetrahydropterin synthase (PTS), and sepiapterin reductase (SPR), respectively
(Figure 1). GCH1 is the rate-limiting enzyme in this pathway and is a major determinant of
BH4 levels [3]. Recent studies have reported that a functional haplotype in the GCH1 gene,
A-T-G (rs8007267-rs3783641-rs10483639), is associated with lower GCH1 gene
expression, lower plasma and vascular BH4 availability, and adverse health outcomes [4, 5].
The complete haplotype is comprised of 15 SNPs, but can be determined by three tagSNPs:
rs8007267 in the promoter region; rs3783641 in intron 1 and rs10483639 in the 3' un-
translated region.
As other potentially oxidative pathologic mechanisms (e.g., maternal pre-gestational
diabetes, obesity, and folate deficiency) are associated with neural tube defects (NTDs) [6–
10]; and as BH4 deficiency may modulate neural tube closure, we hypothesized that BH4
concentrations, as regulated by the GCH1 haplotype, are associated with NTDs. Therefore,
we evaluated the role of offspring and maternal GCH1 haplotypes defined by these three
tagSNPs on the risk of NTDs in the National Birth Defects Prevention Study (NBDPS).
2. MATERIALS AND METHODS
2.1 Subjects
The study population included NTD case-parent triads (n = 760) from the NBDPS, with
estimated dates of delivery between January 1, 1999 and December 31, 2007. Details of the
NBDPS have been published elsewhere [11]. In brief, the NBDPS is a population-based,
case-control study of major structural birth defects. For the period 1999–2007, case infants
with one or more congenital anomalies were ascertained through ten birth defects
surveillance systems throughout the United States (Arkansas, California, Georgia, Iowa,
Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah) and included live
births, stillbirths, and induced pregnancy terminations. NTDs included in the NBDPS had
British Pediatric Association (BPA) codes for the diagnoses anencephaly (740.0),
craniorachischisis (740.1), spina bifida (741.0), and encephalocele (742.0). Abstracted data
for all NTD case infants were reviewed by clinical geneticists using specific criteria,
including standardized case definitions and confirmatory diagnostic procedures [12].
Infants/fetuses with known single gene disorders or chromosomal abnormalities were
excluded from the NBDPS. Mothers completed a one-hour computer assisted telephone
interview (CATI) in English or Spanish between 6 weeks and 2 years after the estimated
date of delivery. The interview included sections on maternal conditions and illnesses,
lifestyle and behavioral factors, and multivitamin use.
2.2 Genotyping Analysis
Buccal brushes from mothers, fathers, and infants were collected as part of the NBDPS [13].
DNA was extracted from buccal cells. A standard quality control procedure was applied to
each sample before they were submitted to the NBDPS sample repository [13]. To assure
genotyping proficiency, high quality, and high concordance among all NBDPS laboratories,
annual evaluations are conducted to confirm the performance of each laboratory (See
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Supplemental Material). Our laboratory at the University of Texas Austin Dell Pediatric
Research Institute has passed all of these evaluations with a score of 100%. SNPs were
assayed using TaqMan method on the ABI PRISM® 7900HT Sequence Detection System
(Life Technologies Corporation, Carlsbad, CA). Genotype calls were made by TaqMan®
Genotyper Software v1.0.1. SNP allele designation used in our paper is consistent with the
dbSNP (reference genome assembly, NCBI Build 37.3).
2.3 Statistical Analysis
The characteristics of cases and parents were summarized using counts and proportions for
the following variables: phenotype (spina bifida, anencephaly, encephalocele); infant sex
(male, female); maternal age (<20, 20–34, ≥35 years); race/ethnicity (non-Hispanic White,
non-Hispanic Black, Hispanic, other); education (<12, 12, 13–15, >15 years); folic acid
supplementation during three months before conception through the first month of
pregnancy (no, yes); body mass index (underweight [<18.5 kg/m2], average weight [18.5–
24.9 kg/m2], overweight [25.0–29.9 kg/m2], and obese [≥30.0 kg/m2]; and pre-pregnancy
diabetes (no, yes). For each analyzed polymorphism, samples for which a genotype could
not be assigned and triads that had genotype combinations that were inconsistent with
Mendelian inheritance were determined. For each subject, the number of genotyping failures
(i.e., genotypes that could not be assigned) was determined. These analyses were performed
using Intercooled Stata, version 12.1 (StataCorp LP, College Station, TX).
An extension of the log-linear model was used to assess the association between NTDs and
both offspring and maternal haplotypes. This was done using HAPLIN version 4.0 (http://
www.uib.no/smis/gjessing/genetics/software/haplin/), running under R version 2.14.0 (R
Foundation for Statistical Computing) [14]. HAPLIN estimates the relative risk (RR) of a
single-or double-dose of each haplotype using a maximum likelihood approach. In instances
where phase is unknown, it is constructed using available family information. Incomplete
triads are included and missing information is imputed using the expectation maximization
algorithm [14]. Haplotypes are estimated using information from all available subjects;
therefore the derived haplotype frequencies are identical for mothers and offspring. A
threshold of 2% for haplotype frequency was used to avoid the inclusion of rare haplotypes.
For each haplotype, a RR and 95% confidence interval (95% CI) was estimated. The RR is a
comparison of the specific haplotype compared to the reference group of the remaining
haplotypes. The single-dose RR is the change for an individual carrying one copy
(heterozygotes of the haplotype), and the double-dose RR compares homozygotes of the
haplotype to the remaining subjects. In addition, a P-value for the overall effect of all
haplotypes in the GCH1 gene was determined using a likelihood ratio test to compare the
log-linear model between a full model, which included terms for the effects of all haplotypes
in each gene, with null models that included no effects. Additionally, analyses were
conducted among those triads with spina bifida only to determine whether the results
obtained using data from all triads were influenced by heterogeneity within the full group.
We did not conduct analyses among those triads with only anencephaly or encephalocele
due to small numbers.
3. RESULTS
Participation in the NBDPS for the period 1999–2007 was 74% among NTD case mothers,
yielding 1,553 families available for analysis. Among those, 760 (49%) provided buccal
brushes (1,791 individuals). Genotyping was performed on DNA samples derived from
these 760 families. Based on quality control checks, one family was excluded for being
inconsistent with Mendelian inheritance at more than one genotype. Additionally, 114
subjects were excluded for failure on more than one genotype, leaving a total of 740 case-
parent triads (97% of the original sample). Of those, 296 were complete triads, 340 were
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dyads, and 104 were monads with only one person in the family. After these quality control
measures were applied, at least 96% of the samples for each variant were available for
analyses; therefore the genotypes were considered of sufficiently high quality.
The distributions of key characteristics among NTD case-parent triads are presented in
Table 1. Spina bifida was the most common phenotype among case subjects (n = 451,
61.0%). Furthermore, a majority of case mothers were non-Hispanic White (n = 443,
60.2%). The only characteristics presented in Table 1 that were significantly different
between interviewed case mothers who provided buccal brushes and those who did not were
race/ethnicity (the proportion of non-Hispanic White mothers was higher among those who
provided buccal brushes) and education (the proportion of mothers with >12 years of
education was higher among those who provided buccal brushes), data not shown.
Table 2 includes the RR estimates and 95% CIs for the association between offspring and
maternal GCH1 haplotypes (rs8007267-rs3783641-rs10483639). Four haplotypes (C-T-C,
C-T-G, T-A-C and T-A-G, had allele frequencies above the threshold (0.02) ranging from
3.89 (95% CI: 2.47–6.12) for T-A-G to 73.27 (95% CI: 69.22–77.03) for C-T-G (allele
frequencies for each SNP are included in Supplemental Table 1). The P-value for the overall
effect of all haplotypes was 0.08. The following haplotypes were not significantly associated
with NTD risk: C-T-G, T-A-C, and T-A-G. However, offspring with two copies of the C-T-
C haplotype had a greater risk of developing an NTD compared to all other offspring (RR =
3.40, 95% CI: 1.02–11.50), after adjusting for the maternal genetic effect. Additionally,
mothers with two copies of the C-T-C haplotype were more likely to have offspring with an
NTD (RR = 3.46, 95% CI: 1.05–11.00), after adjusting for the offspring genetic effect.
These results were similar (e.g., the estimated RRs were similar) when analyses were
restricted to spina bifida cases only, therefore only results in the full group are presented.
4. DISCUSSION
In one of the largest studies of its kind using data from the NBDPS, we observed significant
associations between offspring and maternal GCH1 haplotypes and NTD risk. Specifically,
case infants and mothers with two copies of the C-T-C haplotype had more than a 3-fold
increase for NTDs. The C-T-G, T-A-C, and T-A-G haplotypes were not associated with
NTD risk.
GCH1 and genes encoding other key enzymes in the BH4 biosynthetic pathway are
expressed during early embryonic stage and are known to play an important role in central
nervous system development [15]. Although there is no direct evidence regarding the
functional effect of the C-T-C haplotype, previous studies have demonstrated that haplotype
variability in GCH1 is associated with the enzymatic activity and BH4 bioavailability [4].
The “functional” haplotype originally reported by Antoniades and colleagues [4] was
observed in our study population with a haplotype frequency of 1.19% and could not be
evaluated owing to its low frequency.
An important strength of our study is use of data from the NBDPS, the largest population-
based study of birth defects, which provided a unique opportunity to examine both maternal
and offspring genetic effects on NTD risk. Furthermore, we employed a case-parent triad
design, which is immune to confounding by race/ethnicity (i.e., population stratification) in
the assessment of offspring genotypes [16]. The log-linear modeling approach to analyses
also allowed us to include data from incomplete triads (i.e., genotype data is missing for one
or two individuals) [14, 17]. An additional strength of the NBDPS is the extensive and
standardized case review employed by clinical geneticists, which maximizes homogeneity
among case groups.
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The main weakness of this study was the limited proportion of families with biologic
samples available (49%). The low percentage of families on which the genetic findings are
based could limit our ability to generalize these findings. However, the demographic
differences between those who were included in this study and those who were not, is not
expected to be associated with genotypes. Moreover, it is unlikely that those who chose to
contribute samples were substantially different in genotypes to those who did not.
Additionally, although we had a relatively large sample size, since the significant haplotypes
were relatively uncommon (haplotype frequencies ~5%), we were not able to conduct
additional stratified analyses (e.g., based on additional phenotypes or folic acid
supplementation).
To our knowledge, this is the first study evaluating the GCH1 haplotype in the BH4
biosynthesis pathway as possible risk factors for NTDs. A significant association with the
haplotype in offspring GCH1 gene was observed. The results suggest that disrupted BH4
biosynthesis may contribute to abnormal neural tube closure. Replication of these findings in
other populations and further investigation on the BH4 biosynthesis and regeneration
pathways as potential mechanisms contributing to the population burden for NTDs is
warranted.
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• Plasma BH4 may be associated with neural tube defects (NTDs)
• GCH1 haplotype affects BH4 bioavailability
• We evaluated the GCH1 haplotype in 760 NTD trios
• Offspring with two copies of haplotype C-T-C had a significantly increased
NTD risk
• Mothers with the same haplotype had an increased risk of having an affected
child
• These results suggest variation in the GCH1 haplotype may contribute to NTD
risk
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Figure 1. De novo biosynthesis and regeneration of tetrohydrobiopterin (BH4)
The pathway for the de novo biosynthesis of BH4 from GTP involves GTP cyclohydrolase I
(GCH1), 6-pyruvoyl-tetrahydropterin synthase (PTS) and sepiapterin reductase (SPR).
GCH1 catalyzes the rate-limiting step. The regeneration requires pterin-4a-carbinolamine
dehydratase (PCD) and quinoid dihydropteridine (qBH2) and dihydropteridin reductase
(DHPR).
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Table 1




 Spina bifida 451 61.0
 Anencephaly 215 29.1
 Encephalocele 73 9.9
Infant sex
 Male 336 47.7
 Female 368 52.3
Maternal age (years)
 <20 82 11.1
 20–34 558 75.5
 ≥35 99 13.4
Race/ethnicity
 Non-Hispanic White 443 60.2
 Non-Hispanic Black 34 4.6
 Hispanic 219 29.8
 Other 40 5.4
Education (years)
 <12 137 18.5
 12 187 25.3
 13–15 227 30.7
 >15 188 25.5
Folic acid supplementation
a
 No 346 46.8
 Yes 393 53.2
Body mass index (kg/m2)
 Underweight (<18.5) 28 4.0
 Normal (18.5–24.9) 340 48.9
 Overweight (25.0–29.9) 151 21.7
 Obese (≥30.0) 176 25.3
Pre-pregnancy diabetes
 No 725 98.1
 Yes 14 1.9
a
Three months before conception through the first month of pregnancy
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Table 2
Offspring and Maternal GCH1 Haplotype and the Risk of Neural Tube Defects
Haplotype




 C-T-C 4.88 (3.36–7.12) Single 0.98 (0.56–1.74) 0.94
Double 3.40 (1.02–11.50) 0.04
 C-T-G 73.27 (69.22–77.03) Single 0.91 (0.47–1.74) 0.77
Double 0.98 (0.47–2.07) 0.96
 T-A-C 17.71 (14.54–21.29) Single 1.49 (0.89–2.50) 0.14
Double 1.46 (0.60–3.47) 0.39
 T-A-G 3.89 (2.47–6.12) Single 0.59 (0.27–1.26) 0.17
Double 2.72 (0.38–19.80) 0.32
Maternal
 C-T-C 4.88 (3.36–7.12) Single 1.32 (0.84–2.04) 0.22
Double 3.46 (1.05–11.00) 0.03
 C-T-G 73.27 (69.22–77.03) Single 1.00 (0.57–1.78) 0.99
Double 1.24 (0.68–2.34) 0.50
 T-A-C 17.71 (14.54–21.29) Single 1.01 (0.67–1.51) 0.98
Double 1.30 (0.70–2.45) 0.41
 T-A-G 3.89 (2.47–6.12) Single 0.68 (0.37–1.24) 0.20
Double 3.47 (0.70–18.00) 0.13
a
Haplotypes are named using the reference alleles on the forward strand, Genome Build 37.3.
b
Comparison of the specific haplotype compared to the reference group of the remaining haplotypes
Mol Genet Metab. Author manuscript; available in PMC 2013 November 01.
